Trial Profile

Long-Term Bosutinib for Philadelphia Chromosome–Positive Advanced Chronic Myeloid Leukemia after Prior Tyrosine Kinase Inhibitor Failure

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bosutinib (Primary)
Indications Chronic myeloid leukaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

31 Jul 2015 New trial record
14 Jun 2015 Interim results presented at the 20th Congress of the European Haematology Association.
14 Jun 2015 First results in fully-enrolled cohort of ongoing study presented at the 20th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com